In a recent conference session titled “Rethinking Alzheimer’s: Stories of Strength and Innovation,” Linda Sommerlade, Head of Operations at GT Diagnostics, delivered a compelling presentation on the advancements and future possibilities in diagnosing and managing Alzheimer’s disease.
Genting TauRx Diagnostic Centre Sdn Bhd (GTD), a Malaysian based company, and its UK subsidiary, GT Diagnostics (UK) Ltd, jointly GT Diagnostics, today announced the release of HiPAL Pro, which is now available in the USA.
According to the World Alzheimer report 2021, globally ageing populations plus diagnostic and treatment breakthroughs will create a tsunami of demand for healthcare systems.
Alzheimer’s research UK (ARUK), the largest dementia research conference in the UK, took place in Aberdeen this year. It brought together researchers and healthcare professionals from the field of dementia to discuss the latest developments and research issues.
Diagnosing dementia, or Alzheimer’s disease – its most common form – is a challenging and lengthy process. The current patient journey is a long and winding road. But why is that the case? Let us look at the diagnostic pathway in more detail.
Patient appointments are a bottleneck in the diagnostic pathway of dementia. A diagnosis typically requires several visits, often to different specialists. In addition, only very limited time is allotted for cognitive assessments during patient appointments.
